In many malignancies, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), myeloma, bladder cancer, stomach cancer, glioblastoma, hepatocellular carcinoma, ovarian cancer, breast cancer, colon cancer, head and neck squamous cell carcinoma, and pancreatic neuroendocrine neoplasm (pNEN), a positive response has been observed to treatment regimens based on CD47 blockade [23,25,26,27,28,39,50,51,52,53]. This evidence concerns the gene CD47 and urinary bladder carcinoma.